Is Insulet (PODD) Cheap As Omnipod Growth Faces New Competition Concerns?
Conference spotlight and shifting investor sentiment around Insulet
Insulet (PODD) heads into a Wells Fargo healthcare conference appearance as its Omnipod expansion story meets fresh scrutiny, after Artisan Partners exited the stock over rising insulin pump competition.
Recent price action shows that momentum in Insulet has cooled, with the share price falling over the past week and quarter, and the 1-year total shareholder return down 59.67% despite product updates, a planned Omnipod 6 launch, and the Artisan Partners exit, which is reshaping how investors assess its risk and growth profile.
Scan beyond Insulet and see how other diabetes and medical device players compare on growth and pricing power with the hand picked 49 high quality undervalued stocks.
Insulet still runs a focused, growing diabetes platform, yet the share price has fallen sharply and the market cap now sits near US$10.2b. Does that gap signal a bargain or a fair reset on what this business is worth today?
Most Popular Narrative: 38% Undervalued
Insulet’s most followed valuation story pegs fair value at about $228 per share, well above the last close near $142, which puts a spotlight on the growth assumptions behind that gap.
Expansion into a large underpenetrated U.S. type 2 diabetes population, supported by recent ADA guideline updates recommending AID for insulin users and a starting AID penetration below 5%, points to a long runway for new Omnipod starts. This feeds recurring revenue and supports earnings growth.
Want to see what fuels that kind of valuation for Insulet? The narrative focuses on compounding revenue, rising margins, and a future earnings profile that is expected to look very different from today. Curious which specific growth and profitability targets would need to align to reach that fair value number?
Result: Fair Value of $228.10 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, this Insulet story can break if type 2 diabetes retention stays weak, or if manufacturing issues and recalls continue to increase costs and undermine brand trust.
Find out about the key risks to this Insulet narrative.
Next Steps
Questioning whether the crowd is too gloomy on Insulet or not cautious enough today is a healthy place to start. Move quickly from headline sentiment to hard numbers by reviewing the 4 key rewards.
Looking for more investment ideas beyond Insulet?
Keep your momentum going and line up your next move with a fresh set of opportunities before the market prices them in without you.
- Target potential mispricings by scanning a curated set of quality stocks trading below their estimated worth using the 49 high quality undervalued stocks.
- Build a steadier income stream by focusing on companies that pair higher yields with endurance through the 6 dividend fortresses.
- Shield your portfolio from unpleasant surprises by hunting for financially resilient businesses through the 82 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com